Methylation-based Prognostic Assay for Barrett's Esophagus

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Capsulomics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.

Eligibility Criteria

This trial is for board-certified gastroenterologists in the U.S. who have been practicing for over 2 years, speak English, see at least 50 Barrett's esophagus patients a year, and have internet access. They should not have used the methylation assay test before.

Inclusion Criteria

Be currently practicing board-certified gastroenterologist practicing in the United States

Have practiced (as a board-certified gastroenterologist) for greater than 2

Be English-speaking

+4 more

Participant Groups

The study tests how doctors decide on surveillance and treatment for Barrett's esophagus when given educational materials about a new prognostic methylation-based assay developed by Capsulomics.

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment1 Intervention

The intervention group will receive standard-of-care clinical data for their virtual cases along with educational materials about the methylation assay. This group will then be provided with methylation assay data to be used in addition to clinical data.

Group II: Control GroupActive Control1 Intervention

The control group will receive standard-of-care clinical data for their virtual patient cases. No educational material on the methylation assay will be provided.